Literature DB >> 27412121

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

Antonio D'Avolio1, Debora Pensi2, Lorena Baietto2, Giovanni Pacini3, Giovanni Di Perri2, Francesco Giuseppe De Rosa2.   

Abstract

Infections, including sepsis, are associated with high mortality rates in critically ill patients in the intensive care unit (ICU). Appropriate antibiotic selection and adequate dosing are important for improving patient outcomes. Daptomycin is bactericidal in bloodstream infections caused by Staphylococcus aureus and other Gram-positive pathogens cultured in ICU patients. The drug has concentration-dependent activity, and the area under the curve/minimum inhibitory concentration ratio is the pharmacokinetic/pharmacodynamic (PK/PD) index that best correlates with daptomycin activity, whereas toxicity correlates well with daptomycin plasma trough concentrations (or minimum concentration [C min]). Adequate daptomycin exposure can be difficult to achieve in ICU patients; multiple PK alterations can result in highly variable plasma concentrations, which are difficult to predict. For this reason, therapeutic drug monitoring could help clinicians optimize daptomycin dosing, thus improving efficacy while decreasing the likelihood of serious adverse events. This paper reviews the literature on daptomycin in ICU patients with sepsis, focusing on dosing and PK and PD parameters.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27412121     DOI: 10.1007/s40265-016-0610-3

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  109 in total

1.  Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia.

Authors:  F Pea; M Crapis; P Cojutti; M Bassetti
Journal:  Infection       Date:  2013-07-25       Impact factor: 3.553

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.

Authors:  Federico Pea; Piergiorgio Cojutti; Rodolfo Sbrojavacca; Barbara Cadeo; Francesco Cristini; Alessandro Bulfoni; Mario Furlanut
Journal:  Ann Pharmacother       Date:  2011-07-12       Impact factor: 3.154

Review 4.  Therapeutic drug monitoring of intracellular anti-infective agents.

Authors:  Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Di Perri
Journal:  J Pharm Biomed Anal       Date:  2014-04-03       Impact factor: 3.935

5.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 6.  Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis.

Authors:  Danilo Fliser; Jan T Kielstein
Journal:  Nat Clin Pract Nephrol       Date:  2006-01

7.  A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.

Authors:  Marialuisa Polillo; Carlo Tascini; Marianna Lastella; Paolo Malacarne; Laura Ciofi; Bruno Viaggi; Guido Bocci; Francesco Menichetti; Romano Danesi; Mario Del Tacca; Antonello Di Paolo
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

8.  Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Thomas P Lodise; Nimish Patel; Christopher D Hoy; Shari Meola; Harold J Manley; George L Drusano; Darren W Grabe
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-10       Impact factor: 8.237

9.  Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?

Authors:  Marco Falcone; Alessandro Russo; Maria Iris Cassetta; Angela Lappa; Luigi Tritapepe; Gabriella d'Ettorre; Stefania Fallani; Andrea Novelli; Mario Venditti
Journal:  J Infect Chemother       Date:  2013-01-30       Impact factor: 2.211

10.  Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots.

Authors:  Lorena Baietto; Antonio D'Avolio; Simone Pace; Marco Simiele; Cristina Marra; Alessandra Ariaudo; Giovanni Di Perri; Francesco Giuseppe De Rosa
Journal:  J Pharm Biomed Anal       Date:  2013-08-28       Impact factor: 3.935

View more
  5 in total

1.  Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment.

Authors:  Milo Gatti; Laura Elisa Gasparini; Matteo Laratta; Anna Sigurtà; Anna Rossi; Paolo Brioschi; Osvaldo Chiara; Chiara Vismara; Francesco Scaglione; Sergio Arlati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-03-06       Impact factor: 3.267

Review 2.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

4.  In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci.

Authors:  Jiepeng Tong; Yiheng Jiang; Hao Xu; Xuehang Jin; Li Zhang; Shuaibing Ying; Wei Yu; Yunqing Qiu
Journal:  Drug Des Devel Ther       Date:  2021-07-12       Impact factor: 4.162

5.  Quantification of 15 Antibiotics Widely Used in the Critical Care Unit with a LC-MS/MS System: An Easy Method to Perform a Daily Therapeutic Drug Monitoring.

Authors:  Catherine Feliu; Celine Konecki; Tristan Candau; Damien Vautier; Cyril Haudecoeur; Claire Gozalo; Yoann Cazaubon; Zoubir Djerada
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.